Abstract The goal in external beam radiotherapy for cancer is to maximize tumor-damage while limiting toxic effects of radiation on nearby healthy anatomies. This is achieved through spatial localization and temporal dispersion of radiation dose. Once a radiation intensity profile that achieves the maximum possible spatial localization is designed at the beginning of a multi-week treatment-course, the total planned dose is split into a series of predetermined equal-dosage fractions delivered daily so that healthy cells can recover between sessions. Thus, existing mathematical methods for treatment planning employ static-deterministic optimization techniques, and hence, cannot adapt to a tumor's uncertain biological response over time. In this tutorial, we review a recently proposed stochastic control framework, where the ultimate objective is to design individualized treatment strategies that dynamically adapt to tumorresponse, to deliver the right dose to the right location at the right time.
Introduction
The 2008 World Cancer Report [8] estimated that by 2030 there could be 17 million cancerdeaths annually worldwide. It also predicted that by 2010, cancer would replace heart disease as the leading cause of deaths. In the United States of America, about half of all cancer patients undergo some form of radiotherapy 1 . In external beam radiotherapy, a linear accelerator ( Figure 1 ) is used to pass ionizing radiation through the affected part of the patient's body in order to kill tumor cells. Radiation targeted toward the cancerous regions however also passes through other nearby anatomies, thus damaging both tumor and healthy cells. The goal therefore is to maximize the differential between tumor cell-kill and damage to healthy cells. Radiotherapy planners attempt a two-pronged approach, which involves spatial localization and temporal dispersion of radiation-dose 2 , to reach this objective.
Spatial localization of dose
At the beginning of the treatment planning process, the cancerous targets, and nearby unspecified normal tissue and organ(s)-at-risk (OAR) (collectively, "normal tissue"), are often delineated on an anatomical image such as a computed tomography (CT) or a magnetic resonance imaging (MRI) scan. Intensity modulated radiation therapy (IMRT) technology is then used to tune the radiation field's intensity profile so that the dose delivered to the tumor is much higher than that to the normal tissue [45] . This basic idea is shown in Figure 2 (a). One way to effect precise intensity modulation involves controlling the position and speed of movements of the leaves of a multi-leaf collimator, shown in Figure 2 (b), that is fitted in the aperture of the linear accelerator gantry. Radiation fields from multiple directions are often used as shown in Figure 2 (c) to avoid tumor cold-spots, that is, regions where insufficient dose would otherwise be delivered in an attempt to spare the normal tissue. In mathematical models, each beam is discretized into smaller segments called beamlets. A common practice is to perform inverse planning, that is, to start with a treatment protocol that prescribes a uniform high dose to the cancerous targets and sets a tolerance limit on the dose to normal tissue. Beamlet intensities are then optimized to attain a dose distribution that is as close as possible to this shape-conforming prescription. This is called the fluence-map problem. Several conformal treatment protocols and corresponding fluencemap optimization models and algorithms have been developed and embedded in commercial software over the years. Many of these are surveyed in [10, 20, 33] . Basic background on these models is provided here. For notational brevity, only one tumor and one OAR are considered, ignoring unspecified normal tissue.
In a typical fluence-map optimization problem, regions within a patient's body are modeled using small 3D cubes called voxels. Let n be the number of tumor voxels and m the number of OAR voxels. Let k be the number of radiation beamlets. and let A be the (n + m) × k dose deposition matrix. Its tumor rows (assumed without loss of generality to be the first n rows) are denoted A τ , whereas A ø are its OAR rows. Such a matrix is obtained using radiation transport simulations or pencil beam algorithms [16] . The tumor-dose vector is given by d τ = A τ u ∈ n + ; the dose delivered to tumor voxel i is its ith component d 
where (x) + = max{0, x}, and the w's are artificial weights assigned to the tumor and the OAR [10] . The idea in this model is to minimize total squared deviation of tumor voxel dose from the prescription-dose, and to impose a penalty for overdosing OAR voxels beyond the tolerance level. It is common to include lower and upper bound constraints on dose to tumor voxels, and upper bounds on dose to OAR voxels. Linear programming models and column generation algorithms for fluence-map optimization have also been studied [31] . The dosevolume protocol, which states that no more than a fraction η of the OAR should receive a dose of more than ∆ Gy, is a common source of non-convexity in fluence-map optimization. Mixed integer constraints of the form
where M is a large enough number, can model this [33] . Efforts to optimize the number and angles of radiation beams along with the beamlet intensity levels have also been made [2, 22] . Some recent work on fluence-map optimization has used non-uniform treatment protocols that utilize information from biological images taken at the outset of the treatment course [1, 21, 24, 36, 49] . For instance, a higher dose can be prescribed to regions of high clonogen 3 density within a tumor. Such treatment methods are termed biologically conformal radiotherapy.
In this subsection we outlined the spatial tradeoff in radiotherapy. The temporal aspects of treatment planning are discussed next.
Temporal dispersion of dose
Radiotherapy is typically administered daily over several weeks to give healthy cells time to recover between sessions. This is called fractionation (Figure 3 ). It is partly motivated by the empirical observation that healthy cells have better damage repair ability than tumors. More generally, repair of sublethal damage in normal tissue, redistribution and re-oxygenation of tumor cells into more radiosensitive phases, and repopulation of tumor cells, are important determinants of the efficacy of fractionated radiotherapy [14] . Progression of these complex dynamic biological processes, and hence a patient's biological response to treatment, are difficult to model, uncertain, and vary depending on how the total dose is broken into fractions. Existing treatment planning methods take a static-deterministic view where first an intensity profile is obtained by solving a fluence-map problem at the beginning of the treatment course, and then, the corresponding total dose is delivered by breaking it into a series of equal-dosage fractions. Some representative exceptions to this are outlined next.
An optimal control approach to fractionation was attempted in [40] with various tumorresponse dynamics. But because that research predated the appropriate technological developments, it did not model the fluence-map problem. A similar approach was pursued in [46] , although with more sophisticated tumor dynamics. Again, normal tissue and intensity modulation were ignored. These papers also did not consider uncertainties inherent in Figure 3 . An illustration of a typical curve showing damage to normal tissue and of some benefits of fractionation for normal tissue. The curve AE represents the damage to normal tissue as a function of dose administered in one treatment session. The dotted horizontal line marks the normal tissue damage if dose D1 is given in one treatment session. The curve AF-FG-GH, on the other hand, shows the damage inflicted when dose D1 is split into three equal-dose fractions, with curve AF representing the first fraction, FG showing the second fraction and GH the third. Notice that dose D1 causes less damage when broken into these three fractions. As another "dual" example, curve AB-BC-CD shows that dose D2, in spite of being much higher than D1, causes the same normal tissue damage as D1 because D2 is split into three fractions. See the book [14] for extensive details on such "cell-survival" curves. tumor-response. In [18] , we attempted to incorporate response-uncertainties into the planning process. The fractionation problem was modeled as a finite-horizon Markov decision process where the states related to the biological condition of the tumor and the OAR, and the decision variable in each session was the tumor-prescription-dose. For simplicity, we focused on two values for this dose -H for high and L for low. A monotone policy with structure roughly depicted in Figure 4 was observed to be optimal in numerical experiments. However, a simplistic route, somewhat similar to [40] , was followed in [18] in that the intensity profile was not optimized explicitly -the high-level idea was that a dynamically optimized prescription-dose could be employed as an "input" to a stand-alone fluence-map problem solved for each session.
To summarize, state-of-the-art mathematical methods decouple the spatial and temporal aspects of radiotherapy, ignore uncertainty in dynamic biological processes, and in particular, cannot adapt 4 to the patient's actual response over the treatment course. Recent technological advances in biological imaging have enabled researchers to track tumor-response over time. For example, positron emission tomography (PET) radio-labeled with fluorine-18 ( 18 F) and fluorodeoxyglucose (FDG) tracer, or magnetic resonance spectroscopic imaging (MRSI) of choline/citrate ratio can provide spatiotemporal information about tumor clonogen density. PET with iodine-124-iododeoxyuridine can measure tumor proliferation rates.
18 F-MISO PET can map spatiotemporal evolution of hypoxia (lack of oxygen reduces radiosensitivity). See [3, 11, 36, 37] for more details on such imaging methods. At the same time, mathematical models of tumor-response are also becoming more sophisticated [5, 15, 27, 30, 32, 38, 41] . Potential benefits of adapting treatment based on information obtained from biological images taken over several weeks of treatment, and to mathematical models of tumor-response, have recently been documented [36, 37, 39] . A rough schematic of a monotone optimal policy from [18] for setting tumor-prescriptiondose in a typical treatment session. At a fixed level of OAR-damage, a smaller dose is prescribed as more tumor is killed. For a fixed tumor-kill, a smaller dose is prescribed as the OAR-damage increases. In [18] , some distortions to this intuitive structure were observed near the boundary states, and those are not shown in this picture; see [18] for details.
In this tutorial, we review dynamic biologically conformal radiation therapy (DBCRT) [17, 19] , a stochastic control framework that proposes to utilize such biological images and tumorresponse models, to design spatiotemporally optimized, patient-specific, adaptive radiation treatment strategies that incorporate response-uncertainty and that deliver the right dose to the right location at the right time.
Dynamic biologically conformal radiation therapy
Pictorial intuition behind DBCRT is provided in Figure 5 , where a biological image (a, c, and e) is taken before each treatment session. Since a high clonogen density is observed in the northwest corner in (a), a very high dose is deposited in that region; hence only a mediumlow density of clonogens remains there. The clonogens proliferate to only a small extent, hence, (c) shows medium clonogen density in the southwest corner. On the negative side, the OAR receives considerable dose in the first treatment session. This is compensated in the second session by depositing lower dose in parts of the tumor and in the OAR. Therefore, parts of the tumor survive after the second session, which are eradicated in the third session with high intensity beamlets that do not deposit dose in the OAR. In this example, DBCRT deposits at least a 33% smaller dose in the OAR as compared to a static, equal fractions approach, and eradicates the tumor in three sessions; the static approach would take about six sessions to kill the tumor. Note that, even though it might not have been explicit in this schematic example, decisions in one radiotherapy session do affect those in other sessions and hence should not be made independently. DBCRT is a mathematical framework, rooted in discrete-time stochastic control, which formalizes these intuitive ideas.
In DBCRT, the cancerous target and the normal tissue are viewed as parts of a stochastic dynamic system whose states track a spatial map of relevant information observed in biological images. We assume that an image is acquired at the beginning of each treatment session (a discussion on imaging frequency is included in Section 2.4). Beamlet intensities in each treatment session are the control variables. The objective is to maximize a quantitative measure of the efficacy of adaptive treatment.
In [17, 19] , a general stochastic control formulation of the problem outlined above is presented. The specific structure of this control problem depends on the choices made for Figure 5 . Three chronologically ordered treatment sessions illustrating key conceptual ideas in DBCRT. The L-shaped gray region is the tumor, whereas the blue square in the northeast corner is the OAR. The yellow shapes in the tumor mark clonogen density levels seen in biological images (BI) such as FDG-PET or choline/citrate MRSI. Disk = high density, triangle = medium, cross = medium-low, star = low density. The small hatched squares indicate minor damage to the OAR. Treatment is delivered using two perpendicular beams, each discretized into six beamlets (arrows). Arrow height indicates beamlet intensity level. Long = high intensity, medium length = medium, short = medium low, and very short = low intensity. The patient's condition at the end of three treatment sessions is shown in (g).
defining states of the tumor-normal tissue system, the corresponding system-dynamics equations, the uncertainty model used, and the choice of treatment efficacy measure. Various possibilities for these are described in [17] and we expect that many more will emerge in the future. In this tutorial, we present key ideas in DBCRT through perhaps the simplest yet intuitive and sufficiently insightful choices for these entities -tumor states are defined through clonogen densities in its sub-regions, OAR states use the concept of biologically effective dose (BED), and the treatment objective is to minimize the total number of tumor cells while limiting OAR damage. The discussion here closely follows [17, 19] , but it is simplified in notation, and excludes several details about the algorithms, design of numerical experiments, and computational results. We use the following notation in the rest of this tutorial.
• T =the number of treatment sessions indexed t = 1, 2, . . . , T .
• k=the number of beamlets.
• u t ∈ k + is the k-dimensional vector of beamlet intensities used in treatment session t.
• n=the number of tumor sub-regions indexed i = 1, 2, . . . , n.
• m=the number of OAR sub-regions indexed j = 1, 2, . . . , m.
• A=the (n + m) × k-dimensional dose deposition matrix as described in Section 1.
Notice again that we focus on tumor and OAR and ignore unspecified normal tissue for brevity. Moreover, we assume for simplicity in notation that the m OAR sub-regions come from the same anatomy. This is easily relaxed by putting subscripts j on various OAR parameters that appear in the discussion below. Finally, we assume that all tumor subregions have the same volume and similarly for all OAR sub-regions.
OAR and tumor state definitions and dynamics
An initial difficulty in designing a dynamic treatment strategy lies in appropriately capturing the effect of a possibly non-constant sequence of doses on the OAR. In particular, we need a quantitative way to tell whether a dynamic treatment scheme can be tolerated by an OAR. This challenge arises partly because empirical evidence suggests that the biological effect of dose on OAR is not additive across treatment sessions [14] . For example, the OAR damage induced by two sessions with 2 and 3 Gy, respectively, is not the same as that inflicted by those with 1 and 4 Gy. In addition, traditional dose-tolerance limits for OAR are based on equal-dosage fractionation schemes. For instance, suppose a hypothetical OAR is known to tolerate a total of 20 Gy if delivered in ten sessions of 2 Gy each (this is called a 2Gy × 10 treatment). Owing to the lack of additivity of biological effects, this need not imply that the OAR will be able to tolerate a 10Gy × 2 treatment, or three sessions with 10, 7, and 3 Gy, respectively. Figure 3 illustrates these ideas.
One way to tackle this is to use the notion of biologically effective dose (BED) [14] . To understand this concept, we need to first introduce the well-known log-linear-quadratic model of OAR cell-kill [14] . According to this model, the fraction of OAR cells that survive a treatment session in which the OAR receives a dose of d Gy is given by exp(−αd − βd 2 ).
Here α and β are parameters that depend on the OAR under consideration. This implies that the fraction of OAR cells that survive t treatment sessions with doses d 1 , d 2 , . . . , d t , respectively, equals
Thus, according to the log-linear-quadratic model, the quantity
determines the OAR-damage induced by the sequence (d 1 , d 2 , . . . , d t ). In fact, it is more common to work with ratios (α/β) and hence we consider the expression
obtained after dividing (5) by α. This expression is called the biologically effective dose (BED) of the dose-sequence (d 1 , d 2 , . . . , d t ). Now suppose an OAR is known to tolerate a conventional equal-dosage fractionation scheme of c Gy per session for N sessions. Note that the BED of this scheme equals cN (1 + c/(α/β)).
Here cN is the total dose delivered to the OAR and is denoted D tol for "tolerance dose". We assume that the sequence (d 1 , d 2 , . . . , d t ) can be tolerated by this OAR if its BED is less than the conventional BED; that is, if
This allows us to define the set of feasible beamlet intensities in (11) below. Another advantage of BED is that it yields a simple BED-update formula from one treatment session to the next. To see this, consider the sequence
Then we have
Based on this discussion, we use the BED of the dose-sequence delivered in treatment sessions 1, 2, . . . , t−1 to OAR sub-region j as its state at the beginning of session t. We denote this state by x φ t,j . Let x φ t denote the m-dimensional column vector with components x φ t,j for j = 1, 2, . . . , m. Using other notation set forth earlier, this leads to the OAR state-dynamics
starting with x φ 1,j = 0 for all j = 1, 2, . . . , m, because the initial BED is zero. Thus, the set of feasible beamlet intensities in treatment session t is given by
Now we discuss tumor dynamics. Let x τ t,i denote the density of tumor cells in tumor sub-region i at the beginning of treatment session t as observed say in a PET or MRSI scan. The n-dimensional column vector x τ t , with components x τ t,i for i = 1, 2, . . . , n, defines the biological state of the tumor. We use a stochastic log-linear tumor cell-kill model here. In particular, the cell density in tumor sub-region i is assumed to evolve according to
where θ t,i are non-negative random variables. In this tutorial, we make the simplifying assumption that random variables θ t,i are independent across treatment sessions t as well as across sub-regions. For instance, θ t,i can be thought of as θ t,i or as θ + t,i where θ is a deterministic constant and t,i is random noise independent across i and t. This equation is derived from the more well-known deterministic log-linear-quadratic model [14] using the following reasoning. Williams et al. [47] surveyed forty eight different types of tumors and found that the logarithmic cell-kill is relatively linear over the dose-range of clinical interest. A random variable is used here as the parameter of the cell-kill model to incorporate uncertainties in tumor-response into the planning process. We use the total number of tumor cells remaining (TNTCR) at the end of the treatment course as the measure of treatment efficacy. Because of our assumption that tumor subregion volumes are equal, TNTCR is proportional to
In the next subsection, we present a stochastic control formulation based on the above discussion.
A stochastic control formulation
We denote the state of the tumor-OAR system at the beginning of session t by
Given that the initial tumor cell density vector is x τ 1 and the initial BED is the zero vector, the set of all possible tumor-OAR states x t at the beginning of session t is denoted S t . We denote the set of feasible intensity vectors u t ∈ k + as defined in (11) by U t (x t ). The set of all treatment policies is denoted Π. This Π is the set of all sequences π = (π 1 , . . . , π t , . . . , π T ), where π t , for each t = 1, 2, . . . , T , is a mapping that assigns a feasible intensity vector π t (x t ) ∈ U t (x t ) to state x t ∈ S t . Then, DBCRT calls for finding a treatment policy π ∈ Π that solves the stochastic control problem
subject to dynamics
Backward recursive solution of Bellman's equations of dynamic programming is a standard theoretical technique for computing an optimal policy for (15) [6] . It is not implementable here however as it calls for the solution of an uncountable number of minimization problems. A discretization is not practical either owing to the curse-of-dimensionality [6, 28] . We therefore outline a few other possibilities, used in [17, 19] , for approximately solving the above stochastic control problem. The books by Bertsekas [6] and Powell [28] are excellent resources for more details about these and other algorithms for approximate dynamic programming.
Some options for approximate dynamic programming
Deterministic control The simplest approach is to ignore all uncertainty assuming the θ t,i 's take some nominal valuesθ t,i , say their expected values, and solve a deterministic version of (15) . It suffices to search over sequences of feasible beamlet intensities u 1 , u 2 , . . . , u T based solely on the initial state. This is called an open loop solution. We view this staticdeterministic method as the base case, as it resembles current practice. BED is monotone increasing over t and therefore, in a static problem, it suffices to enforce the BED constraints only at t = T . As the initial BED is zero, the problem simplifies to
subject to
It is shown in [19] that problem (16) is convex. With recent advances in convex programming [7] , we expect that it should typically be possible to solve it efficiently.
Open Loop Control (OLC) The OLC approach finds an open loop solution by solving the convex stochastic programming problem
Certainty Equivalent Control (CEC) This method begins by replacing future uncertainty with nominal valuesθ t,i , thus leading to a deterministic problem. It is solved to obtain a sequence of controls; only the first control is implemented, discarding the rest. The system then evolves stochastically to the next state, and the process is repeated until termination.
Thus, T deterministic problems need to be solved over a treatment course of T sessions; the t th problem, starting in state x t , is given by
It is shown in [19] that problem (18) is also convex.
Open Loop Feedback Control (OLFC)
This technique is similar to CEC but future uncertainty is not replaced with nominal values; rather an open loop expected value minimization is performed. Thus, T convex stochastic programming problems of the form (19) are solved.
Numerical experiments
Extensive numerical experiments and detailed analyses of their results for multiple computer-generated tumor-OAR prototypes are presented in [17, 19] . Here we briefly outline the key observations from some of those results. The initial experiments focussed on demonstrating, using prototypes with spatially as well as temporally inhomogeneous 5 tumors, that DBCRT can simultaneously balance spatiotemporal tradeoffs in radiotherapy -a capability that existing mathematical optimization methods do not have. A comparison of the above four approximate control methods using a computer-generated U-shaped tumor-OAR geometry similar to that in Figure 2 (c) was then performed. In these experiments, the tumor-radiosensitivity parameters α t,i were assumed to be independent and identically distributed scaled-Beta 6 and the TNTCR objective, averaged over independent simulations, was compared. Based on the computation times and the corresponding TNTCR values shown in Figure 6 , CEC was seen to be an effective approximation method as it was fast and yet achieved a relatively low TNTCR. The average TNTCR with CEC was about 73% less as compared to deterministic control, which, as stated earlier, is a static-deterministic approach and hence is conceptually analogous to existing fluence-map optimization techniques. Additional numerical experiments with CEC using a simplified 2D head-and-neck cancer geometry showed 64% and 98% improvement in average TNTCR as compared to deterministic control, respectively for low and high degrees of clonogen inhomogeneity within the tumor. The impact of imaging frequency will likely be an important factor in future clinical implementation of DBCRT. How many imaging sessions will be economically, and Figure 6 . A comparison of four approximate solution methods. The x-axis shows computation times normalized with respect to the computation time of deterministic control (det). The y-axis shows the normalized average TNTCR over independent Monte Carlo simulations. Plotted using numbers reported in [17, 19] . clinically feasible over a treatment course remains to be seen. Therefore, we wanted to quantify the expected value of information obtained through state observations. In [17] , the DBCRT framework was extended to the case where an image, i.e., a state observation, is acquired every K ≥ 1 treatment sessions. Figure 7 shows the decrease in TNTCR with increasing imaging frequency for one prototype in [17] with twelve treatment sessions. The figure suggests that even one additional observation in the middle of the course may reduce TNTCR. This is consistent with conjectures made in [39] regarding patient-specific radiotherapy based on clinical intuition.
Clinical challenges and opportunities for future research
DBCRT is in its early stages of development. It is currently only a mathematical modeling and optimization framework. Several practical challenges will need to be overcome if it is to become a clinical reality. Some of the hurdles we foresee in this endeavor, possible solutions, and corresponding research opportunities are briefly outlined in this section.
First and foremost, the aforementioned and other efficient approximate solution algorithms will have to be tested extensively on realistic-scale computer-generated 3D test cases, perhaps using commercial treatment planning systems. This will have to be followed by clinical trials.
One difficulty is related to imaging quality -how much biological information can accurately be gleaned from biological images to effectively guide decisions? Clearly, the better the biological image-quality, the larger the potential benefit of an adaptive method like DBCRT. Significant progress has been made in this direction over the last decade [4, 13, 23, 25, 26, 42, 43] , and medical physicists and doctors now increasingly seem to believe that patient-specific biologically guided radiotherapy will be technologically feasible within a decade (see page 3747 of [39] for a detailed discussion and a pictorial representation of a strategy for clinical implementation). On the mathematical side, imaging noise could be incorporated using imperfect state information models in stochastic control [6, 44] .
The simplest radiation-response models were employed in this tutorial. As more sophisticated models become available, they could be incorporated into the general DBCRT framework in [17, 19] . No matter which response-models are used, for truly patient-specific treatment, parameters of the models will have to be estimated for each individual patient based on information gathered from biological images taken over the treatment course. Several statistical estimation methods could be investigated. Such an integrated learning and control framework would fall within the realm of adaptive control [6] and would provide interesting opportunities for future research.
In [17, 18, 19] , the total number of treatment sessions was fixed a priori . Although this is a common practice in radiotherapy, there is a considerable debate about what the "optimal" number of treatment sessions should be. To address this, a preliminary optimal stopping variation of DBCRT was introduced in [17] . The idea was to decide, at each treatment session, whether it is worthwhile to continue treatment; if treatment is to be continued, then an optimal beamlet intensity profile is computed and implemented in that treatment session. In that approach, treatment is continued if the benefit of an additional session exceeds its "cost", which may include financial, patient inconvenience, and normal tissue-damage components. We foresee interesting opportunities for algorithmic research in this area.
